These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 36551260)

  • 1. The Potential Roles of Post-Translational Modifications of PPARγ in Treating Diabetes.
    Ji X; Zhang W; Yin L; Shi Z; Luan J; Chen L; Liu L
    Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlling a master switch of adipocyte development and insulin sensitivity: covalent modifications of PPARγ.
    Floyd ZE; Stephens JM
    Biochim Biophys Acta; 2012 Jul; 1822(7):1090-5. PubMed ID: 22504298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A
    Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PPARγ signaling and metabolism: the good, the bad and the future.
    Ahmadian M; Suh JM; Hah N; Liddle C; Atkins AR; Downes M; Evans RM
    Nat Med; 2013 May; 19(5):557-66. PubMed ID: 23652116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.
    Cho N; Momose Y
    Curr Top Med Chem; 2008; 8(17):1483-507. PubMed ID: 19075761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pleiotropic effects of PPARγ agonist on hemostatic activation in type 2 diabetes mellitus.
    Ferroni P; Della-Morte D; Pileggi A; Riondino S; Rundek T; Ricordi C; Guadagni F
    Curr Vasc Pharmacol; 2013 May; 11(3):338-51. PubMed ID: 23650948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PPARγ signaling and emerging opportunities for improved therapeutics.
    Wang S; Dougherty EJ; Danner RL
    Pharmacol Res; 2016 Sep; 111():76-85. PubMed ID: 27268145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revisiting PPARγ as a target for the treatment of metabolic disorders.
    Choi SS; Park J; Choi JH
    BMB Rep; 2014 Nov; 47(11):599-608. PubMed ID: 25154720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances on PPARγ Research in the Emerging Era of Precision Medicine.
    Lu P; Zhao Z
    Curr Drug Targets; 2018; 19(6):663-673. PubMed ID: 28641522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin resistance and PPAR insulin sensitizers.
    Bhatia V; Viswanathan P
    Curr Opin Investig Drugs; 2006 Oct; 7(10):891-7. PubMed ID: 17086933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.
    Derosa G; Maffioli P
    Curr Mol Pharmacol; 2012 Jun; 5(2):272-81. PubMed ID: 22122457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recent trends in PPARgamma agonist development of thiazolidinediones and non-thiazolidinediones].
    Tanaka T
    Nihon Rinsho; 2010 Feb; 68(2):249-55. PubMed ID: 20158092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.
    Soccio RE; Chen ER; Lazar MA
    Cell Metab; 2014 Oct; 20(4):573-91. PubMed ID: 25242225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions.
    Schopfer FJ; Cole MP; Groeger AL; Chen CS; Khoo NK; Woodcock SR; Golin-Bisello F; Motanya UN; Li Y; Zhang J; Garcia-Barrio MT; Rudolph TK; Rudolph V; Bonacci G; Baker PR; Xu HE; Batthyany CI; Chen YE; Hallis TM; Freeman BA
    J Biol Chem; 2010 Apr; 285(16):12321-33. PubMed ID: 20097754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity.
    Choi SS; Kim ES; Koh M; Lee SJ; Lim D; Yang YR; Jang HJ; Seo KA; Min SH; Lee IH; Park SB; Suh PG; Choi JH
    J Biol Chem; 2014 Sep; 289(38):26618-26629. PubMed ID: 25100724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists.
    Darwish KM; Salama I; Mostafa S; Gomaa MS; Helal MA
    Eur J Med Chem; 2016 Feb; 109():157-72. PubMed ID: 26774923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.
    Li Y; Wang Z; Furukawa N; Escaron P; Weiszmann J; Lee G; Lindstrom M; Liu J; Liu X; Xu H; Plotnikova O; Prasad V; Walker N; Learned RM; Chen JL
    J Biol Chem; 2008 Apr; 283(14):9168-76. PubMed ID: 18263587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular basis of selective PPARgamma modulation for the treatment of Type 2 diabetes.
    Gelman L; Feige JN; Desvergne B
    Biochim Biophys Acta; 2007 Aug; 1771(8):1094-107. PubMed ID: 17459763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting peroxisome proliferator-activated receptor gamma for generation of antidiabetic drug.
    Karak M; Bal NC; Bal C; Sharon A
    Curr Diabetes Rev; 2013 Jul; 9(4):275-85. PubMed ID: 23746081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetes: New conductors for the peroxisome proliferator-activated receptor γ (PPARγ) orchestra.
    Whitehead JP
    Int J Biochem Cell Biol; 2011 Aug; 43(8):1071-4. PubMed ID: 21558015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.